INFOGRAPHIC: Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy
17. 5. 2024
Obstructive hypertrophic cardiomyopathy (HCM) is most commonly caused by disorders of cardiac muscle proteins. How does targeted treatment for this disease work? We bring a concise, graphically processed overview of the efficacy and mechanism of action of the first selective cardiac myosin inhibitor.
„Zkrácenou informaci o přípravku naleznete zde”
https://www.bms.com/assets/bms/cz/en/documents/CAMZYOS_ZIP.pdf
Stáhněte si praktické schéma:
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
